Pluristem Therapeutics Set to Enter Bone Marrow Disease Market as it is Preparing to Apply for Orphan Drug Status With the FDA for the Treatment of Aplastic Bone Marrow

HAIFA, Israel, July 23, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it is preparing to apply to the U.S. Food and Drug Administration for approval of its PLacental eXpanded (PLX) cells for the treatment of aplastic bone marrow as an Orphan Drug. Gaining Orphan Drug status approval is part of Pluristem's strategy for penetrating the bone marrow recovery market, starting with treatment of aplastic anemia, a disease in which bone marrow greatly decreases or stops production of blood cells and which strikes five to ten people in every million.